Table 1.
Baseline patient characteristics of patients with TP53-wild type AML who were refractory to or relapsed after frontline therapy
| Characteristic (N=200) | Median [range] / N (%) |
|---|---|
| Age, years | 69 [17–94] |
| Therapy-related AML | 26 (13) |
| Frontline therapy | |
| Intensive chemotherapy | 69 (35) |
| Low-intensity therapy | 131 (66) |
| Response to frontline therapy | |
| Relapsed | 115 (58) |
| Refractory | 85 (43) |
| European LeukemiaNet 2017 risk | |
| Favorable | 21 (11) |
| Intermediate | 94 (47) |
| Adverse | 85 (43) |
| Cytogenetics | |
| Diploid | 87 (44) |
| 11q23 rearrangement | 7 (4) |
| −7 | 31 (16) |
| −5/−5q | 15 (8) |
| Complex | 41 (21) |
| Other abnormalities | 19 (10) |
| Mutations * | |
| SRSF2 | 1¼6 (24) |
| DNMT3A | 46 (23) |
| IDH2 | 39 (20) |
| NRAS | 36 (18) |
| ASXL1 | 35 (18) |
| RUNX1 | 33 (17) |
| FLT3-ITD | 32 (16) |
| TET2 | 30 (15) |
| NPM1 | 29 (15) |
| DDX41 | 3/23 (13) |
| IDH1 | 22 (11) |
| CEBPA | 22 (11) |
| SF3B1 | 3/31 (10) |
| PTPN11 | 14 (7) |
| U2AF1 | ¾6 (7) |
| ETV6 | 3/51 (6) |
| FLT3-D835 | 10 (5) |
| KRAS | 10 (5) |
*
Only mutations present in ≥5% of cases are included